Heterogeneity in the treatment of moderately severe scalp psoriasis in Scotland – results of a survey of Scottish health professionals

References

• Skincare Conditions in Scotland: What the Healthcare Professionals Think. A report of a survey of service provision for patients with dermatological conditions. October 2008. SSCIG, The Scottish Skincare Conditions Industry Group. Available at: http://www.abpi.org.uk/Scotland/pdf/SSCIGSurveyFinalReportOct08.pdf [Last accessed 18 June 2010]
   Google Scholar
• Woolacott N, Hawkins N, Mason A, et al. Etanercept and efalizumab for the treatment of psoriasis: a systematic review. Health Technol Assess 2006;10:1
   PubMed Web of Science ®Google Scholar
• Gelfand JM, Weinstein R, Porter SB, et al. Prevalence and treatment of psoriasis in the United Kingdom. A population-based study. Arch Dermatol 2005;141:1537-41
   PubMed Web of Science ®Google Scholar
• Farber EM, Nall L. Natural history and treatment of scalp psoriasis. Cutis 1992;49:396-400
   PubMed Web of Science ®Google Scholar
• van de Kerkhof PC, Steegers-Theunissen RP, Kuipers MV. Evaluation of topical drug treatment in psoriasis. Dermatol 1998;197:31-6
   PubMed Web of Science ®Google Scholar
• Van de Kerkhof PC, de Hoop D, de Korte J, et al. Scalp psoriasis, clinical presentations and therapeutic management. Dermatol 1998;197:326-34
   PubMed Web of Science ®Google Scholar
• Bardazzi F, Fanti PA, Orlandi C, et al. Psoriatic scarring alopecia: observations in four patients. Int J Dermatol 1999;38:765-8
   PubMed Web of Science ®Google Scholar
• Poyner TF, Fell PJ. A survey of patients with plaque psoriasis who had not consulted their doctor in the past year. Br J Clin Res 1995;6:201-7
   Google Scholar
• Lundberg L, Johannesson M, Silverdahl M, et al. Quality of life, health-state utilities and willingness to pay in patients with psoriasis and atopic eczema. Br J Dermatol 1999;141:1067-75
   PubMed Web of Science ®Google Scholar
• Chen SC, Yeung J, Chren MM. Scalpdex: a quality of life instrument for scalp dermatitis. Arch Dermatol 2002;138:803-7
   PubMed Web of Science ®Google Scholar
• Chan CS, van Voorhees AS, Lebwohl MG, et al. Treatment of severe scalp psoriasis: From the Medical Board of the National Psoriasis Foundation. Am Acad Dermatol 2009;60:962-71
   PubMed Web of Science ®Google Scholar
• Lebwohl M. A clinician’s paradigm in the treatment of psoriasis. J Am Acad Dermatol 2005;53:S59-S69
   PubMed Web of Science ®Google Scholar
• Papp K, Berth-Jones, J, Kragballe K, et al. Scalp psoriasis: a review of current topical treatment options. J Eur Acad Dermatol Venereal 2007;21:1151-60
   PubMed Web of Science ®Google Scholar
• Mason J, Mason AR, Cork MJ. Topical preparations for the treatment of psoriasis: a systematic review. Br J Dermatol 2002;146:351-64
   PubMed Web of Science ®Google Scholar
• Koo J. Current consensus and update on psoriasis therapy: a perspective from the U.S. J Dermatol 1999;26:723-33
   PubMedGoogle Scholar
• Gottlieb AB. Psoriasis. Dis Manag Clin Outcome 1998;1:195-202
   Google Scholar
• van der Kerkhof PC, Franssen ME. Psoriasis of the scalp. Diagnosis and management. Am J Clin Dermatol 2001;2:159-65
   PubMedGoogle Scholar
• Feldman SR, Housman TS. Patients’ vehicle preference for corticosteroid treatments of scalp psoriasis. Am J Clin Dermatol 2003;4:221-4
   Google Scholar
• Guenther LC. Treatments for scalp psoriasis with emphasis on calcipotriol plus betamethasone dipropionate gel (Xamiol®). Skin Therapy Letter 2009;14(4). Available at: http://skintherapyletter.com/download/stl_14_4.pdf [Last accessed 29 November 2010]
   Google Scholar
• Buckley C, Hoffmann V, Shapiro J, et al. Calcipotriol plus betamethasone dipropionate scalp formulation is effective and well tolerated in the treatment of scalp psoriasis: a phase II study. Dermatology 2008;217:107-13
   PubMed Web of Science ®Google Scholar
• Jemec GBE, Ganslandt C, Ortonne JP, et al. A new scalp formulation of calcipotriene plus betamethasone compared with its active ingredients and the vehicle in the treatment of scalp psoriasis: a randomised, double-blind, controlled trial. J Am Acad Dermatol 2008;59:455-63
   PubMed Web of Science ®Google Scholar
• Van de Kerkhof P, Hoffmann V, Anstey A, et al. A new scalp formulation of calcipotriene plus betamethasone in the treatment of scalp psoriasis compared to its active ingredients in the same vehicle. Br J Dermatol 2009;160:170-6
   PubMed Web of Science ®Google Scholar
• Kragballe K, Hoffmann V, Ortonne JP, et al. Efficacy and safety of calcipotriol plus betamethasone dipropionate scalp formulation compared with calcipotriol scalp solution in the treatment of scalp psoriasis. Br J Dermatol 2009;161:159-66
   PubMed Web of Science ®Google Scholar
• Tyring S, Appell M, Bibby A, et al. Calcipotriene/betamethasone dipropionate gel compared to gel vehicle in treating scalp psoriasis in Hispanic/Latino and black/African American patients. J Am Acad Dermatol 2008;58(2 Suppl. 2):AB125
   Web of Science ®Google Scholar
• Tyring S, Mendoza N, Appell M et al. A calcipotriene/betamethasone dipropionate two-compound scalp formulation in the treatment of scalp psoriasis in Hispanic/Latino and Black/African American patients: results of the randomised, 8 week, double-blind phase of a clinical trial. Int J Dermatol 2010:49:1328-33
   Google Scholar
• Luger TA, Cambazard F, Larsen FG, et al. A study of the safety and efficacy of calcipotriol and betamethasone dipropionate scalp formulation in the long-term management of scalp psoriasis. Dermatology 2008;217:321-28
   PubMed Web of Science ®Google Scholar
• Ortonne JP, Ganslandt C, Tan J, et al. Quality of life in patients with scalp psoriasis treated with calcipotriol/betamethasone dipropionate scalp formulation: a randomized controlled trial. J Eur Acad Dermatol Venereol 2009;23:919-26
   PubMed Web of Science ®Google Scholar
• Patel B, Siskin S, Krazmien R, et al. Compatibility of calcipotriene with other topical medications. J Am Acad Dermatol 1998;38:1010-11
   PubMed Web of Science ®Google Scholar
• Simonsen L, Høy G, Didriksen E, et al. Development of a new formulation combining calcipotriol and betamethasone dipropionate in an ointment vehicle. Drug Dev Ind Pharm 2004;30:1095-102
   PubMed Web of Science ®Google Scholar
• Freeman K, Marum M, Bottomley JM, et al. A psoriasis-specific model to support decision-making in practice – UK experience. Curr Med Res Opin 2011;27:205-23
   Google Scholar
• Scottish Medicines Consortium. Guidance to manufacturers. Question and answer document on economic submissions to the Scottish Medicines Consortium. Available at: http://www.scottishmedicines.org/smc/files//Economic%20question%20and%20answer%20document%20(Master%20Nov%2004).pdf [Last accessed 22 June 2010]
   Google Scholar
• Scotland’s Population 2007. The Registrar General’s Annual Review of Demographic Trends. 153rd Edition. General Register Office for Scotland 2008. Available at http://www.gro-scotland.gov.uk/files1/stats/scotlands-population-2007-the-register-generals-annual-review-153rd-edition/scotlands-population-2007-the-register-generals-annual-review-153rd-edition.pdf
   Google Scholar
• Rees J. The characteristics of an enigmatic disease. Psoriasis in Practice 2002;1:1-3
   Google Scholar
• Berth-Jones J. Psoriasis. Medicine 2005;33:50-5
   Google Scholar
• Woolacott N, Hawkins N, Mason A, et al. Etanercept and efalizumab for the treatment of psoriasis: a systematic review. Health Technol Assess 2006;10:1
   PubMed Web of Science ®Google Scholar
• Gelfand JM, Weinstein R, Porter SB, et al. Prevalence and treatment of psoriasis in the United Kingdom. A population-based study. Arch Dermatol 2005;141:1537-41
   PubMed Web of Science ®Google Scholar
• van de Kerkhof PCM, Steegers-Theunissen RPM, Kuipers MV. Evaluation of topical treatment in psoriasis. Dermatology 1998;197:31
   PubMed Web of Science ®Google Scholar
• Wozel G. Psoriasis treatment in difficult locations: scalp, nails, and intertriginous areas. Clin Dermatol 2008;26:448-59
   PubMed Web of Science ®Google Scholar
• Recommendations for the initial management of psoriasis. British Association of Dermatologists and Primary Care Dermatology Society. Guidelines 2009;39:395-6. Available at http://www.eGuidelines.co.uk [Last accessed 18 June 2010]
   Google Scholar
• Zaghloul S, Goodfield M. Objective assessment of compliance with psoriasis treatment. Arch Dermatol 2004;140:408-14
   PubMed Web of Science ®Google Scholar
• Bottomley JM, Taylor RS, Ryttov J. The effectiveness of two-compound formulation calcipotriol and betamethasone dipropionate gel in the treatment of moderately severe scalp psoriasis: a systematic review of direct and indirect evidence. Curr Med Res Opin 2011;27:251-68
   Google Scholar
• Affleck AG, Bottomley JM, Auland ME, et al. Cost-effectiveness of the two-compound formulation calcipotriol and betamethasone dipropionate gel in the treatment of scalp psoriasis in Scotland. Curr Med Res Opin 2011;27:269-84
   Google Scholar
• Scottish Medicines Consortium. Calcipotriol and betamethasone dipropionate, 50 micrograms/g+500 microgram/g gel (Xamiol®). No. 559/09. 10 July 2009. Available at http://www.scottishmedicines.org/smc/files/Microsoft%20Word%20-%20calcipotriol%20and%20betamethasone%20dipropionate%20_Xamiol_%20FINAL%20July%202009%20for%20website.pdf [Last accessed 4 November 2009]
   Google Scholar